Novo Nordisk has provided advance notice that it will discontinue Saxenda, its brand of liraglutide 3 mg for chronic weight management, with last shipments to wholesalers taking place in late January 2027.
This is a manufacturer decision to withdraw a product, not a supply disruption and not a safety action. Saxenda was approved by the FDA in December 2014 — the first GLP-1 approved for weight management — and was later approved for patients aged 12 and older.
If you take Saxenda, you have a planning window rather than an emergency. But planning windows close, and the worst version of this is finding out at the pharmacy counter. This article sets out what is happening, what your options are, and what to raise with your prescriber.
The Facts, Briefly
Last Shipments: Late January 2027
Novo Nordisk states last shipments to wholesalers take place in late January 2027. Pharmacy stock will persist for some period beyond that, but you should not plan around residual supply.
A Generic Was Approved in August 2025
The FDA approved the first generic liraglutide injection for long-term weight management in adults with obesity, or overweight with weight-related conditions. It works the same way as the brand and carries full FDA review.
The Generic Is Not Dramatically Cheaper
Generic liraglutide has been listed around $1,084 for a comparable quantity, against a Saxenda list price of $1,349.02 for a five-pen package. Cheaper, but not the collapse a generic approval often produces.
Compounded Liraglutide Exists but Is Limited
Hone Health lists compounded liraglutide from $160 per month plus a membership fee. Compounded preparations are not FDA-approved and have not been reviewed for safety, efficacy or manufacturing quality.
For Many Patients the Answer Is a Weekly Agent
Liraglutide generally produces less weight loss than weekly semaglutide or tirzepatide and requires daily injection. If liraglutide was chosen because it was what was available, this is the moment to revisit that.
Adolescent Patients Are Affected Differently
Saxenda was approved down to age 12, and paediatric approvals in this class remain limited. For adolescent patients the discontinuation is more consequential, and generic liraglutide is likely the relevant continuity conversation.
Your Four Realistic Options
There is no single right answer here. Which of these is appropriate depends on why you are on liraglutide in the first place — and that is the question to bring to your prescriber.
1. Switch to Generic Liraglutide
The cleanest continuity option if liraglutide is working for you. FDA-approved since August 2025, same molecule, same mechanism, no compounded regulatory uncertainty. Listed around $1,084, so check whether your plan covers the generic where it may have declined the brand.
2. Switch to a Weekly GLP-1
Semaglutide or tirzepatide, injected once weekly rather than daily, with substantially greater average weight loss. Compounded routes start from around $99 a month all-inclusive; brand-name routes are available through manufacturer channels with published self-pay pricing.
3. Compounded Liraglutide
Hone Health lists it from $160 per month plus membership, which is far below brand or generic pricing. The trade-off is that compounded preparations are not FDA-approved. Ask which pharmacy dispenses and whether it is 503A or 503B.
4. A Non-GLP-1 Approved Medication
If GLP-1 tolerability has been part of why you are on the lowest-intensity option, Qsymia at $70 a month or Contrave at $99 are FDA-approved oral alternatives working through entirely different mechanisms.
The Question to Answer First
Before choosing between those options, answer this: why are you on liraglutide rather than a weekly agent?
If there was a specific clinical reason — you could not tolerate semaglutide or tirzepatide, your clinician judged daily titration control was better for you, you are an adolescent patient where approved options are limited, or your insurance covered liraglutide and not the newer agents — then that reason still applies, and generic or compounded liraglutide is the natural direction.
If the honest answer is that liraglutide is simply what you started on, perhaps years ago before the weekly agents were widely available or affordable, then the discontinuation is doing you a favour by forcing a conversation you would benefit from having anyway. Weekly semaglutide and tirzepatide produce more weight loss with one injection a week instead of seven, and compounded routes now cost a fraction of what liraglutide costs.
What to Raise With Your Prescriber
Bring these to your next appointment rather than waiting for the transition to become urgent.
Are we switching to generic liraglutide or changing molecules?
This is the fork. Ask your prescriber to be explicit about which they recommend and why, rather than defaulting to the generic because it is administratively simplest.
Will my insurance cover the generic?
A plan that declined brand-name Saxenda may cover the generic, or may not. Formulary treatment of a new generic is not automatic. Check before you need the prescription filled.
If we switch molecules, what does the transition look like?
Moving from daily liraglutide to weekly semaglutide or tirzepatide involves a new titration schedule. Ask what the plan is, what side effects to expect during the change, and how quickly you can reach someone if it goes badly.
Am I on liraglutide for a reason that still applies?
The most useful question in the whole conversation. If there is a clinical reason, it should be nameable. If there is not, the discontinuation is an opportunity rather than a problem.
For adolescent patients: what is approved and available?
Saxenda’s approval extended to patients aged 12 and older, and paediatric approvals in this class remain limited. This decision belongs entirely with the treating clinician and family, and warrants a dedicated conversation.
Our Take
Raise this at your next appointment, not your last one before January 2027. A planned transition — with your insurance checked, your molecule decision made, and a titration schedule agreed — is a completely different experience from finding out at a pharmacy counter that your prescription cannot be filled.
For most adults, the honest recommendation is to use this as a prompt to reconsider the molecule. Liraglutide generally produces less weight loss than weekly semaglutide or tirzepatide, and requires seven injections a week rather than one. If it was chosen for a specific clinical reason, stay on it via the generic. If it was simply what was available, weekly agents are now both more effective and, through compounded routes such as Coreage RX at a flat $99, dramatically cheaper.
If liraglutide is genuinely right for you, the generic is the cleanest route — FDA-approved, same molecule, available through standard pharmacy channels. Check whether your plan covers it, since a new generic is not automatically on formulary. Hone Health is the main compounded alternative at from $160 plus membership, with the caveat that compounded preparations are not FDA-approved.
For adolescent patients, this warrants its own conversation. Saxenda was approved down to age 12 and paediatric approvals in this class are limited, which makes the withdrawal more consequential. That decision belongs entirely with the treating clinician and family.
Frequently Asked Questions
When exactly is Saxenda discontinued?
Novo Nordisk has provided advance notice that it will discontinue Saxenda, with last shipments to wholesalers taking place in late January 2027. Pharmacy stock will persist for some period after that, but you should plan your transition rather than relying on residual supply.
Why is Saxenda being discontinued?
This is a manufacturer decision to withdraw the product. It is not a supply disruption and not a safety action. The FDA approved the first generic liraglutide injection for long-term weight management in August 2025, which provides a continuity route for patients on the molecule.
Will generic liraglutide be available?
Yes. The FDA approved the first generic liraglutide injection in August 2025 for long-term weight management in adults with obesity, or overweight with weight-related conditions. It works the same way as Saxenda and carries full FDA review of safety, efficacy and manufacturing quality.
How much does generic liraglutide cost?
Generic liraglutide has been listed around $1,084 for a comparable quantity, against a Saxenda list price of $1,349.02 for a five-pen package. Cheaper than the brand, but not the dramatic reduction generic approval often implies. Price it at your own pharmacy and check whether your plan covers it.
Should I switch to Wegovy or Zepbound instead?
For many adults, yes — but it depends on why you are on liraglutide. If there was a specific clinical reason, it still applies. If liraglutide was simply what was available when you started, weekly semaglutide or tirzepatide produce more weight loss with one injection a week rather than seven, and compounded routes cost a fraction of liraglutide pricing.
Can I stockpile Saxenda before it runs out?
That is not a plan we would recommend, and it is not a decision to make independently. Liraglutide pens have storage requirements and expiry dates, and prescriptions are written for defined quantities. Use the planning window to agree a transition with your prescriber instead.
What about teenagers on Saxenda?
Saxenda was approved for patients aged 12 and older, and paediatric approvals in this medication class remain limited, which makes the discontinuation more consequential for adolescent patients. Generic liraglutide is likely the relevant continuity conversation, but this decision belongs entirely with the treating clinician and family.
Is compounded liraglutide an option?
It exists but sources are limited. Hone Health lists compounded liraglutide from $160 per month plus a membership fee, well below brand or generic pricing. Compounded preparations are not FDA-approved and have not been reviewed for safety, efficacy or manufacturing quality — ask which pharmacy dispenses and whether it is 503A or 503B.
Disclosure:
This article is based on publicly available information including Novo Nordisk’s published advance notice of Saxenda discontinuation and list price disclosures, FDA approval announcements for liraglutide and its first generic, provider-published pricing, and independent pricing checks, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews; we have no relationship with Novo Nordisk. Discontinuation timelines are as announced by the manufacturer and may change. List prices are not what most patients pay — insurance coverage, savings programmes and pharmacy pricing all vary. Compounded medications are not FDA-approved. Nothing here is medical advice, and any change to your medication belongs to a clinician who knows your history. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
Switching GLP-1 Providers
Changing provider without a treatment gap, and what to do if supply stops.
Saxenda Review
The original daily GLP-1, its record and what replaces it.
Where to Get Liraglutide
Every remaining route to the molecule, brand, generic and compounded.
Semaglutide vs Tirzepatide
If you are switching molecules, which weekly agent fits better.
Stopping GLP-1 Medications
What happens when GLP-1 treatment ends, and how to plan for it.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →